Table 2.
Clinical trials using immune checkpoint inhibitors for metabolic treatments.
| Clinical Trial | Drugs | Cancer | ICIs | Targets | Mechanism |
|---|---|---|---|---|---|
| NCT03684811 | Olutasidenib (FT-2102) |
Hepatobiliary tumors | nivolumab (PD-1) | TCA Cycle | Inhibits the tumor growth and oncometabolite 2-HG production |
| NCT04056910 | Ivosidenib (AG-120) | Gliomas, advanced solid tumors | nivolumab (PD-1) | ||
| NCT03048500 | Metformin | Non-small-cell lung cancer | nivolumab (PD-1) | Oxidative phosphorylation | Inhibition of ATP synthesis and tumor growth, AMPK activation |
| NCT03800602 | Colorectal cancer | nivolumab (PD-1) | |||
| NCT03311308 | Melanoma | pembrolizumab (PD-1) | |||
| NCT04114136 | Solid tumors | nivolumab (PD-1) pembrolizumab (PD-1) | |||
| NCT03994744 | Small-cell lung cancer | sintilimab (PD-1) | |||
| NCT04414540 | head and neck squamous cell carcinoma | pembrolizumab (PD-1) | |||
| NCT03618654 | head and neck squamous cell carcinoma | durvalumab (PD-L1) | |||
| NCT02903914 | CB-1158 | Advanced solid tumors | pembrolizumab (PD-1) | Arginine | Inhibition of arginine degradation |
| NCT03254732 | ADI-PEG20 | Advanced solid tumors | pembrolizumab (PD-1) | Promotes degradation of tumor growth promoting arginine | |
| NCT03922880 | Uveal melanoma | nivolumab (PD-1) + ipilimumab (CTLA-4) |
|||
| NCT04899921 | Trigriluzole (BHV-4157) |
lymphoma Solid tumors | ipilimumab (CTLA-4) + nivolumab (PD-1) | Glutamine | Reduction in extracellular level via inhibition of the release of T cells |
| NCT03229278 | Renal cell carcinoma, melanoma, Non-small-cell lung cancer | nivolumab (PD-1) or pembrolizumab (PD-1) | |||
| NCT02771626 | CB-839 | Renal cell carcinoma, melanoma, Non-small-cell lung cancer | nivolumab (PD-1) | Inhibition of cancer cell proliferation and glutaminolysis | |
| NCT03361865 | Epacadostat | Urothelial cancer | pembrolizumab (PD-1) | Tryptophan | Inhibition of Trp-Kyn-AhR pathway and upregulation of tumor immunity |
| NCT03322540 | Non-small-cell lung cancer | ||||
| NCT03374488 | Urothelial cancer | ||||
| NCT03291054 | Gastrointestinal stromal tumors | ||||
| NCT03260894 | Renal cell carcinoma | ||||
| NCT02364076 | Thymic carcinoma | ||||
| NCT03358472 | head and neck squamous cell carcinoma | ||||
| NCT03414229 | Sarcoma | ||||
| NCT02364076 | Thymic carcinoma | ||||
| NCT03196232 | Gastric cancer | ||||
| NCT02298153 | Non-small-cell lung cancer, Urothelial cancer | ||||
| NCT02752074 | Melanoma | ||||
| NCT03463161 | Head and neck cancer | ||||
| NCT03348904 | Non-small-cell lung cancer | ||||
| NCT03602586 | Ovarian cancer | ||||
| NCT03823131 | head and neck squamous cell carcinoma | pembrolizumab (PD-1) + EPT | |||
| NCT02178722 | solid tumors | pembrolizumab (PD-1) | |||
| NCT02318277 | Advanced solid tumors | durvalumab (PD-L1) | |||
| NCT01604889 | Melanoma | ipilimumab (CTLA-4) | |||
| NCT03707457 | Linrodostat (BMS-986205) |
Glioblastoma | nivolumab (PD-1) | ||
| NCT03695250 | Hepatocellular carcinoma | ||||
| NCT03854032 | HNSCC | ||||
| NCT04106414 | Endometrial cancer | ||||
| NCT03329846 | Melanoma | ||||
| NCT02996110 | RCC | ||||
| NCT03192943 | Advanced tumors | ||||
| NCT02935634 | Gastric cancer | ||||
| NCT03335540 | Advanced solid tumors |